Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in HAQ change from baseline Scale from: 0 to 3. compared with placebo (with or without MTX) (moderate certainty).
1 finding from 1 review
- Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 1268 participantsModerate